BillionToOne Q1 revenue $108.4M (+84% YoY), raises FY 2026 guidance to $450M-$465M

BillionToOne, Inc.

2026-Q1 EPS reported $0.34 revenue$108,388,000

Net income $18.0M ($0.34 diluted) vs loss of $4.0M (-$0.39) in Q1 2025.
Gross margin improved to 73% from 64% YoY; operating income $17.8M vs loss $2.3M.
Oncology revenue surged 392% to $10.7M; prenatal revenue up 72% to $96.5M.
Full-year 2026 revenue guidance raised to $450M-$465M from prior $430M-$445M.
Launched Unity Confirm non-invasive confirmation assay for high-risk prenatal results.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

BillionToOne, Inc. reported first quarter ended March 31, 2026 results: revenue $108.4 million, net income $18.0 million, or $0.34 per diluted share, EPS $0.34 per diluted share. Guidance raised.

Period: first quarter ended March 31, 2026
Revenue: $108.4 million
Net income: $18.0 million, or $0.34 per diluted share
EPS: $0.34 per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

to all, today reported its financial results for the first quarter ended March 31, 2026 and raised guidance for full year 2026. Financial Highlights: ● Total revenue of $108.4 million in the first quarter of 2026, compared to $59.0 million in the first quarter of 2025, an increase of 84%. ● Prenatal clinical testing revenue was $96.5 million in the first

View on SEC.gov

Browse all earnings releases →

BillionToOne, Inc. filing history →

Source: SEC EDGAR

accession 0002070849-26-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.